The Client on Isotretinoin Who Wants a Full-Leg Series
A 34-year-old woman books a 90-minute lower-leg series for dense, coarse hair. During intake she reports that she finished a 6-month course of isotretinoin (40 mg daily, cumulative dose roughly 7,200 mg) five weeks ago. She has no scarring, no active lesions, and her skin looks normal on inspection. She is Fitzpatrick type IV and mentions that her last waxing was nine days ago. She is eager to start today because she has a wedding in three months and wants to be 'done' in time. She has read online that some electrologists treat immediately after the drug is stopped and asks you to make an exception. She has no other medical conditions and takes no other medications.
1. What is your decision about treating today, and what is the clinical reasoning behind it?
Read the worked answer
Do not treat today. Isotretinoin alters sebaceous gland function and epidermal turnover and is associated with impaired wound healing and, in some reports, atypical scarring or delayed healing after cutaneous injury. Standard conservative practice is to defer elective epilation for a period after the last dose - commonly cited as around six months, though evidence is limited and protocols vary. The key judgement is that this is elective, not urgent, and the risk of poor healing or scarring on a large treatment area in a type IV skin (higher dyspigmentation risk) outweighs the client's timeline. Five weeks post-course is well inside any reasonable deferral window. Document the decision, the drug, dates, and cumulative dose. Offer a realistic plan: re-evaluate at the agreed interval, and in the meantime discuss temporary hair management that does not traumatize the skin (e.g., trimming, shaving with care) rather than waxing or plucking, which can distort follicles and complicate later treatment.
2. The client asks whether she can sign a waiver so you will treat her anyway. How do you respond, and what does this reveal about consent and scope?
Read the worked answer
A waiver does not convert an unsafe elective treatment into a safe one, and it does not transfer clinical responsibility away from the practitioner. Informed consent is about the client understanding risks, benefits, and alternatives - it is not a mechanism for overriding a contraindication the practitioner judges clinically significant. Explain that you are declining because the treatment is not in her interest at this time, not because of paperwork. Offer a written summary of the reasoning and a timeline. If she presses, remain firm and non-punitive; she is free to seek another provider, but your professional judgement stands. Document the conversation, including that a waiver was offered and declined, and that alternatives and a re-book date were given. This is squarely within Standards of Practice: practising within competence and putting client safety ahead of client preference.
3. At the re-evaluation, what would you assess before starting, and how would you modify the first session?
Read the worked answer
Re-assess skin integrity on the lower legs (no irritation, no active dermatitis), confirm no new medications or pregnancy, and re-check the timeline since last dose against your protocol. Confirm the waxing history has resolved and there is no folliculitis. Then treat conservatively: start with a small test area, use lower intensity and shorter duration, and avoid overlapping insertions. Space the first full session shorter than the requested 90 minutes so you can observe healing before committing to a large area. Give explicit aftercare (cool compresses, bland emollient, sun protection, no harsh products) and schedule a follow-up check of the test area before the next session. Warn about expected erythema and the possibility of post-inflammatory hyperpigmentation in type IV skin, and document all of this. The principle: reintroduce treatment gradually and let observed healing, not the calendar, drive the pace.